Danish Pharmacovigilance Update, November 2016
09 December 2016
In this issue:
- Suicidal behaviour and suicidal ideation have been reported as suspected adverse reactions to the dermatologic medicinal product Otezla® (apremilast)
- Focus on reported adverse reactions to selected biological medicines
- Most recent Direct Healthcare Professional Communications (DHPCs)
- EU's list of recommendations on safety signals
- Danish Pharmacovigilance Update celebrates 7-year anniversary